Drugs through Bugs: Expression of Naglu-‐PTD4 in Spodoptera frugiperda
dc.contributor.author | Ashmead, Rhea | |
dc.date.accessioned | 2016-04-27T21:32:43Z | |
dc.date.available | 2016-04-27T21:32:43Z | |
dc.date.copyright | 2016 | en_US |
dc.date.issued | 2016-04-27 | |
dc.description.abstract | Mucopolysaccharidosis IIIB (MPS IIIB) is a rare metabolic disorder that is caused by a deficiency in the lysosomal hydrolase α-N-acetylglucosaminidase (Naglu). The deficient activity of this enzyme results in the cytotoxic accumulation of heparan sulfate in the lysosome. Patients with this disorder experience progressive central nervous system degeneration and a significantly shortened life span. Presently, enzyme replacement therapy is an ineffective treatment for MPS IIIB due to the inability of exogenous Naglu to permeate the blood-brain barrier. This project uses the Sf9 insect cell system to express human recombinant Naglu fused to a synthetic protein transduction domain with the intent to facilitate the delivery of Naglu across the blood-brain barrier. The overall goal of this project is to establish a large-scale, economical system for the production of human recombinant Naglu that has the potential to be successfully used for enzyme replacement therapy to treat MPS IIIB. | en_US |
dc.description.reviewstatus | Unreviewed | en_US |
dc.description.scholarlevel | Undergraduate | en_US |
dc.description.sponsorship | Jamie Cassels Undergraduate Research Award | en_US |
dc.identifier.uri | http://hdl.handle.net/1828/7217 | |
dc.language.iso | en | en_US |
dc.subject | Sanfilippo Syndrome | en_US |
dc.subject | Mucopolysaccharidosis | en_US |
dc.subject | α-N-acetylglucosaminidase | en_US |
dc.subject | Choy Lab | en_US |
dc.title | Drugs through Bugs: Expression of Naglu-‐PTD4 in Spodoptera frugiperda | en_US |
dc.type | Poster | en_US |